GLP-1 Medications and Cardiovascular Health: Beyond Weight Loss

Medically reviewed by Dr. Kevin Chua, Medical Director

Disclaimer: This article provides general medical information and is not a substitute for professional medical advice.

Introduction

GLP-1 medications were developed to treat diabetes and obesity — but emerging evidence shows they do much more. The landmark SELECT trial demonstrated that semaglutide reduces the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight and obese adults, independent of diabetes status¹. This finding has profound implications for how we think about weight loss treatment — it's not just cosmetic; it's cardioprotective.

The SELECT Trial: What It Found

The SELECT trial was a game-changer for the weight loss medication field, providing definitive evidence that GLP-1 treatment has cardiovascular benefits.

Study Design

• 17,604 adults aged 45+ with overweight/obesity and established cardiovascular disease
• Without diabetes (to isolate the cardiovascular effect from glucose-lowering benefits)
• Semaglutide 2.4 mg weekly vs placebo
• Mean follow-up: 39.8 months

Key Results

• 20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke)
• Benefit observed regardless of baseline BMI
• Consistent across age groups, sex, and geographic regions
• Weight loss of approximately 9.4% with semaglutide vs 0.9% with placebo

Why This Matters

For overweight Singaporean men with cardiovascular risk factors, GLP-1 medications offer a dual benefit: weight loss AND direct cardiovascular protection. This changes the risk-benefit calculation significantly.

How GLP-1 Medications Protect the Heart

The cardiovascular benefits of GLP-1 medications appear to extend beyond weight loss alone. Multiple mechanisms contribute to this cardioprotective effect.

Weight-Loss-Mediated Benefits

• Reduced visceral fat → decreased inflammation and insulin resistance
• Lower blood pressure → reduced cardiac workload
• Improved lipid profile → less atherosclerosis progression
• Better glycaemic control → reduced vascular damage

Direct Cardiovascular Effects

Research suggests GLP-1 receptors are present in the heart and blood vessels, and GLP-1 agonists may directly:

• Reduce inflammation — lower levels of CRP and other inflammatory markers
• Improve endothelial function — better blood vessel health
• Reduce atherosclerotic plaque progression(Based on MOH guidelines and prescribing information)
• Protect against ischaemic damage — cardioprotective during low-oxygen events

Singapore Context: Why This Matters Here

Singapore's population faces specific cardiovascular risks that make these findings particularly relevant.

Singapore Cardiovascular Risk Profile

• Heart disease is the #2 cause of death in Singapore
• High diabetes prevalence — 8.5% of residents; diabetes is a major cardiovascular risk factor
• Metabolic syndrome is common — driven by sedentary lifestyles and dietary patterns
• Hypertension affects 1 in 4 adults — often inadequately controlled
• Dyslipidaemia is widespread — high-cholesterol diets and genetic factors

Practical Implications

For Singaporean men who are overweight with cardiovascular risk factors, GLP-1 medications offer evidence-based treatment that addresses multiple conditions simultaneously:

• Excess weight → weight loss
• Cardiovascular risk → direct risk reduction
• Diabetes risk → improved glucose metabolism
• Inflammation → anti-inflammatory effects

Who Benefits Most from Cardiovascular Protection?

The SELECT trial specifically enrolled individuals with established cardiovascular disease, but the findings likely have broader implications for at-risk populations.

Highest-Benefit Groups

• Men with established cardiovascular disease (prior MI, stroke, or peripheral vascular disease)
• Men with multiple cardiovascular risk factors (hypertension + diabetes + dyslipidaemia)
• Men with metabolic syndrome
• Men with strong family history of premature cardiovascular disease

Lower-Risk Men

For younger men without cardiovascular risk factors, the primary benefit of GLP-1 medications remains weight loss. The cardiovascular protection is an additional benefit that may become more relevant as they age.

Beyond Weight and Heart: Other Emerging Benefits

Ongoing research is exploring additional benefits of GLP-1 medications that extend well beyond their primary indications.

Kidney Protection

The FLOW trial demonstrated that semaglutide slowed kidney disease progression in patients with Type 2 diabetes and chronic kidney disease(Based on MOH guidelines and prescribing information).

Fatty Liver Disease (NAFLD/NASH)

GLP-1 medications reduce liver fat and inflammation, with potential benefits for non-alcoholic fatty liver disease — a common condition in overweight Singaporean men(Based on MOH guidelines and prescribing information).

Sleep Apnoea

Weight loss with GLP-1 medications has been shown to improve obstructive sleep apnoea severity, with some patients able to discontinue CPAP therapy(Based on MOH guidelines and prescribing information).

Cost in Singapore (SGD)

GLP-1 receptor agonist medications for weight management in Singapore typically cost SGD $200–500 per month depending on the specific medication and dosage. Costs vary by provider and whether branded or biosimilar options are available. noah™ offers structured weight loss plans with doctor oversight.

Prices are approximate and may vary. Updated April 2026.

FAQ

1. Do I need heart disease to benefit from the cardiovascular effects?

The SELECT trial enrolled patients with established cardiovascular disease. However, the weight loss, blood pressure reduction, and metabolic improvements benefit anyone at elevated cardiovascular risk — not just those with existing disease.

2. Does this mean GLP-1 medications replace heart medications?

No. GLP-1 medications are additive — they provide benefits alongside existing treatments (statins, antihypertensives, etc.), not as replacements. Continue all prescribed cardiovascular medications.

3. Is Ozempic or Mounjaro better for heart protection?

The SELECT trial used semaglutide. Cardiovascular outcome trials for tirzepatide are ongoing. At present, semaglutide has the strongest cardiovascular evidence, but tirzepatide may show similar benefits.

4. How long do I need to take GLP-1 for cardiovascular benefit?

The SELECT trial showed benefits over a mean follow-up of about 3 years, with effects emerging within the first year. Sustained use is likely needed for sustained cardiovascular protection.

5. Should I ask my cardiologist about GLP-1 medications?

If you're overweight with cardiovascular risk factors or established heart disease, absolutely. The SELECT trial evidence is compelling enough that many cardiologists are now actively recommending GLP-1 medications for eligible patients.

References

→ Return to pillar: Complete Guide to Medical Weight Loss in Singapore

This article is for informational purposes only and does not constitute medical advice. Always consult a licensed doctor before starting any treatment.